Sistema complementario

FD-IN-1 is an orally active Factor D (FD) inhibitor (IC50=12 nM), inhibits Factor XIa and Tryptase β2 with IC50 values of 7.7 and 6.5 μM, respectively.

Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5).

NDT 9513727 is a potent, selective and competitive C5aR1 inverse agonist for the study of inflammatory and immune disorders.

EG00229 blocks VEGF-A/NRP1 binding, IC50 of 3 μM; doesn't affect VEGFR-1/2. It's an NRP1 antagonist.

Factor D inhibitor 6 is a potent, highly selective, and orally active compound that specifically inhibits the activity of factor D (FD) with an IC50 of 30 nM and a Kd of 6 nM. It does not exhibit inhibitory effects against factor B, classical and lectin complement-pathway activation, or a broad array of receptors, ion channels, kinases, and proteases.

Factor B-IN-2 is a potent inhibitor (IC50: 1.5 μM) of complement factor B. Factor B-IN-2 can be used to study inflammatory and immune-related diseases.

W-54011: potent non-peptide C5a receptor blocker; binds 125I-C5a (Ki=2.2nM); stops Ca2+ movement, chemotaxis, ROS in neutrophils (IC50=1.6-3.1nM).

EG01377 is a NRP1 antagonist with antiangiogenic, antimigratory, and antitumor activity, Kd 1.32 μM, IC50s 609 nM for NRP1-a1/b1, inactive on NRP2.

C5aR-IN-1, a potent C5aR inhibitor, may aid in researching autoimmune and inflammatory diseases.

Iptacopan (LNP023) is an inhibitor with high affinity to factor B, with a KD value of 7.9 nM and an IC50 value of 10 nM. Cost-effective and quality-assured.

Pelecopan (BCX9930), an oral complement factor D inhibitor, prevents hemolysis in PNH (IC50=14.3 nM).

(Rel)-Factor B-IN-5 is a complement factor B inhibitor that can be used to study diseases associated with activation of the alternative complement pathway.

Factor B-IN-4 is a potent inhibitor (IC50: 1 μM) of complement factor B. Factor B-IN-4 can be used to study inflammatory and immune-related diseases.

Factor B-IN-3 is a potent inhibitor of complement factor B. Factor B-IN-3 can be used to study inflammatory and immune-related diseases.

Izicopan (INF056) is an antagonist of the complement factor C5a receptor. It inhibits C5a-induced calcium mobilization with an IC50 ranging from 10 to 100 nM.

Refinicopan is a complement factor D inhibitor with an IC50 of 10 nM, demonstrating an inhibition activity on rabbit erythrocyte hemolysis with an IC50 of 41 nM. It possesses excellent pharmacokinetic and pharmacodynamic properties.

4-Octylphenol is an endocrine disruptor with gender-specific effects on male germ cells, significantly reducing the mitotic index and the number of spermatogonia. It also causes inflammatory damage in the gills of carp by activating the complement system through the C3a/C3a receptor (C3a/C3aR) axis and C5a/C5a receptor 1 (C5a/C5aR1) axis. Furthermore, 4-Octylphenol induces immune suppression by disrupting the balance between helper T (Th) cells 1/Th2 and regulatory T (Treg)/Th17 cells, and triggers inflammatory damage through the Toll-like receptor 7 (Toll-like Receptor (TLR))/inhibitor κBα/nuclear factor κB (TLR7/IκBα/NF-κB) pathway.

Factor B-IN-6 is an orally bioavailable inhibitor of Factor B. It exhibits significant inhibitory activity on the activation of the human serum alternative pathway. In model animals, Factor B-IN-6 can improve kidney lesions and function, reducing urinary protein levels. Factor B-IN-6 is applicable for kidney disease research.

C5aR-IN-3, a potent C5aR inhibitor, may treat autoimmune and inflammatory diseases.